1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Malignant Melanoma: KOL Insight

  • November 2015
  • Firstword Pharma
Report ID: 2440013

Summary

Table of Contents

Malignant Melanoma: KOL Insight reveals the impact of immunotherapy on first-line treatment combination choices

The arrival of cancer immunotherapy in 2011 significantly changed the landscape for drugs used by oncologists for treating malignant melanoma. The availability of mutation testing is also impacting the choice of treatments, particularly for targeted therapies. With new approvals for Bristol-Myers Squibb’s Opdivo and Amgen’s T-VEC, the options available continue to grow
As the treatment landscape for malignant melanoma becomes more crowded, you need to understand how and why physicians are making complex decisions about their first-line drug choices. Find out what KOLs are saying about your brands, and the brands of your closest competitors

Answering Key Questions

Recently marketed drugs and vaccines
Yervoy (ipilimumab): Will the drug's adoption, gained from early approval, be threatened by new arrivals with better response rates and reduced toxicity?
Keytruda (pembrolizumab): What role does dosing schedule play in driving preference for this drug?
Opdivo (nivolumab): What concerns still underlie the positive reception of this recently approved therapy?
Cotellic (cobimetinib): Does combination therapy offer a way forward, and will its use depend on side-effects or pricing?
Mekinist (trametinib): For patients with BRAF mutations, what will be the driving factor for selection of combination therapy, and will safety concerns outweigh this in treatment decisions?
Zelboraf (vemurafenib): What is the impact of not having an approved combination on its label in relation to its use as a first-line therapy?
Tafinlar (dabrafenib): Does its side-effect profile give it an edge, or will it lose out if a cobimetinib and vemurafenib combination becomes available?
M-Vax: Has immunotherapy side-lined the role of vaccines in melanoma treatments because of the limited efficacy of vaccines? Or is it useful for a niche subset of patients?
Talimogene laherparepvec (T-VEC): While some activity has been shown, and there is potential benefit for a niche patient group, is this enough to overcome the restrictions and challenges presented by this recently-approved vaccination?

Pipeline drugs and vaccines

Masitinib: Should trials concentrate on the Far East where there is a higher-rate of c-KIT mutated melanoma in order to speed up possible access to an on-label option?
Encorafenib: Is the safety profile going to be enough to get physicians to switch treatments in an already crowded field?
Binimetinib: Is this just another 'me-too' third-line drug or do KOLs, waiting on Phase III trial results, think it has potential for NRAS-mutated patients?
Zastumotide: The results of NSCLC data from an adjuvant setting is already colouring the view of this vaccine. Does it have any future as a malignant melanoma treatment?
Seviprotimut-L (POL 103A): KOLs are still asking big questions about this vaccine – especially about potential results. Will it find a place in the treatment paradigm?
Eltrapuldencel-T: Will the complications of it as a treatment be a barrier to take-up if efficacy is proved?



Key issues explored

Which combinations are KOLs preferring to use as first-line treatments based on efficacy, toxicity and patient profiles?
How new drug combination approvals are likely to effect the first-line choice of treatments in future, and which KOLs are keen to be able to prescribe.
Whether the practical difficulties with resources for testing patients with c-KIT mutations will outweigh the benefits of using a different treatment pathway for relevant patients? Or does this targeting offer a real niche market?
What concerns exist about the sequencing of treatments?
Where KOLs think the alternatives to immunotherapy will find their niche with particular populations.
Some of the surprising factors that can influence choices – from availability of fridges and experience with injections, to paperwork and dosing schedules.
A round-up of the latest clinical trials for each drug included.


Contributors

KOLs from North America
Dr Richard W. Joseph, MD. Assistant Professor of Oncology, Mayo Clinic Health System, Florida, USA.
Dr Igor Puzanov, MD, MSCI, FACP. Associate Professor of Medicine, Vanderbilt University, Nashville, TN, USA.
Dr Rene Gonzalez, MD. Professor of Medicine, Division of Medical Oncology, University of Colorado Denver, USA.
Prof. Bartosz Chmielowski, MD, Ph.D. Assistant Professor, Department of Medicine, UCLA, CA, USA.
Dr Anthony Olszanski, MD, RPh. Medical Oncologist, Fox Chase Cancer Center, Philadelphia, PA, USA.
Dr Stergios Moschos MD. University of North Carolina at Chapel Hill, School of Medicine, UNC Lineberger, Carolina, USA.

KOLs from Europe

Dr Nicolas Blin, MD. Consultant Physician at Nantes University Hospital, France.
Dr J Mayordomo, Ph.D. Medical Director, Translational Research Unit, Albacete University Hospital, Spain.
Dr Maria Elisabetta Fratto, MD. Oncologist, University Campus Bio Medico, Rome, Italy.
German KOL, Prof. Dr. A chief consultant, head of the Clinical Cooperation Unit Dermato-oncology in the Department of Dermatology, Venereology and Allergology at the University Hospital.
Prof. Ruth Plummer, MA, DPhil, BMBCh, MD, FRCP. Consultant Medical Oncologist, Newcastle Upon Tyne Hospitals, UK.
Dr Marianne Nicolson, MD, FRCP. Consultant, Aberdeen Royal Infirmary, Scotland, UK.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update
Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, Nov 2015
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Ulcerative Colitis Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost laye ...

Crohn’s Disease Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Crohn’s disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of ...

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • February 2017
  • by GlobalData

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025 Summary Immune Thrombocytopenia (ITP) is an autoimmune-related bleeding disorder characterized by a low platelet ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Hormone and Therapy Market in Pakistan and the US

  • June 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Vaccine Market and Influenza Statistics in India

  • June 2017
    6 pages
  • Vaccine  

    Influenza  

    Diabetes  

  • India  

    United States  

View report >

Global Antimalarials Market

  • June 2017
    9 pages
  • Antimalarials  

    Hormone  

  • Tanzania  

    Netherlands  

    World  

View report >

Related Market Segments :

Therapy

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.